CY1119552T1 - Μεθοδος αυξησης της οστικης σκληροτητας και ακαμψιας και μειωσης των καταγματων - Google Patents

Μεθοδος αυξησης της οστικης σκληροτητας και ακαμψιας και μειωσης των καταγματων

Info

Publication number
CY1119552T1
CY1119552T1 CY20171101077T CY171101077T CY1119552T1 CY 1119552 T1 CY1119552 T1 CY 1119552T1 CY 20171101077 T CY20171101077 T CY 20171101077T CY 171101077 T CY171101077 T CY 171101077T CY 1119552 T1 CY1119552 T1 CY 1119552T1
Authority
CY
Cyprus
Prior art keywords
strength
reduce
increasing bone
vertebral fractures
incidence
Prior art date
Application number
CY20171101077T
Other languages
English (en)
Inventor
Janet M. Hock
Gregory A. Gaich
Willard H. Dere
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26792729&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1119552(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP06027055A external-priority patent/EP1769804B1/en
Priority claimed from EP02079227A external-priority patent/EP1295605A3/en
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CY1119552T1 publication Critical patent/CY1119552T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/29Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Η εφεύρεση αναφέρεται σε μέθοδο για την αύξηση της σκληρότητας και/ή ακαμψίας των οστών και/ή μείωση της πιθανότητας και/ή σοβαρότητας κατάγματος στα οστά δια της χορηγήσεως μίας παραθυρεοειδούς ορμόνης. Η μέθοδος μπορεί να χρησιμοποιηθεί για την αύξηση της σκληρότητας ή ακαμψίας των οστών σε μία θέση δυνητικού ή πραγματικού τραύματος, όπως το ισχίο ή η σπονδυλική στήλη ενός ατόμου σε κίνδυνο για ή που ή υποφέρει από οστεοπόρωση. Η μέθοδος της εφεύρεσης μπορεί να μειώσει τη συχνότητα σπονδυλικών καταγμάτων, να μειώσει τη συχνότητα πολλαπλών σπονδυλικών καταγμάτων, να μειώσει τη σοβαρότητα σπονδυλικού κατάγματος και/ή να μειώσει τη συχνότητα μη σπονδυλικού κατάγματος.
CY20171101077T 1998-08-19 2017-10-13 Μεθοδος αυξησης της οστικης σκληροτητας και ακαμψιας και μειωσης των καταγματων CY1119552T1 (el)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US9715198P 1998-08-19 1998-08-19
US9974698P 1998-09-10 1998-09-10
EP10180447.4A EP2266598B1 (en) 1998-08-19 1999-08-19 Method of increasing bone toughness and stiffness and reducing fractures
EP06027055A EP1769804B1 (en) 1998-08-19 1999-08-19 hPTH(1-34) for use in preventing or reducing the incidence or severity of vertebral and / or non vertebral fracture in a male human
EP02079227A EP1295605A3 (en) 1998-08-19 1999-08-19 Method of increasing bone toughness and stiffness and reducing fractures
EP99942350A EP1059933B1 (en) 1998-08-19 1999-08-19 Use of parathyroide hormone consisting of aminoacid sequence 1-34 of human parathyroid hormone for reducing the risk of both vertebral and non vertebral bone fracture

Publications (1)

Publication Number Publication Date
CY1119552T1 true CY1119552T1 (el) 2018-03-07

Family

ID=26792729

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20121101096T CY1113343T1 (el) 1998-08-19 2012-11-14 hPTH(1-34) ΓΙΑ ΧΡΗΣΗ ΣΕ ΠΡΟΛΗΨΗ Ή ΜΕΙΩΣΗ ΤΗΣ ΣΥΧΝΟΤΗΤΑΣ Ή ΣΟΒΑΡΟΤΗΤΑΣ ΣΠΟΝΔΥΛΙΚΩΝ ΚΑΙ/Ή ΜΗ-ΣΠΟΝΔΥΛΙΚΩΝ ΚΑΤΑΓΜΑΤΩΝ ΣΕ ΕΝΑΝ ΑΝΤΡΑ
CY20171101077T CY1119552T1 (el) 1998-08-19 2017-10-13 Μεθοδος αυξησης της οστικης σκληροτητας και ακαμψιας και μειωσης των καταγματων

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20121101096T CY1113343T1 (el) 1998-08-19 2012-11-14 hPTH(1-34) ΓΙΑ ΧΡΗΣΗ ΣΕ ΠΡΟΛΗΨΗ Ή ΜΕΙΩΣΗ ΤΗΣ ΣΥΧΝΟΤΗΤΑΣ Ή ΣΟΒΑΡΟΤΗΤΑΣ ΣΠΟΝΔΥΛΙΚΩΝ ΚΑΙ/Ή ΜΗ-ΣΠΟΝΔΥΛΙΚΩΝ ΚΑΤΑΓΜΑΤΩΝ ΣΕ ΕΝΑΝ ΑΝΤΡΑ

Country Status (33)

Country Link
US (2) US6977077B1 (el)
EP (3) EP1059933B1 (el)
JP (5) JP2002523375A (el)
KR (1) KR100454207B1 (el)
CN (1) CN1205997C (el)
AR (1) AR033639A1 (el)
AT (1) ATE231000T1 (el)
AU (1) AU746277B2 (el)
BR (1) BR9909445A (el)
CA (1) CA2325371C (el)
CO (1) CO5130020A1 (el)
CY (2) CY1113343T1 (el)
CZ (1) CZ301017B6 (el)
DE (2) DE15152726T1 (el)
DK (4) DK1769804T3 (el)
DZ (1) DZ2873A1 (el)
EA (1) EA003362B1 (el)
ES (4) ES2549551T3 (el)
HK (3) HK1030545A1 (el)
HR (1) HRP20000755A2 (el)
HU (2) HU1200430D0 (el)
ID (1) ID29039A (el)
IL (2) IL138829A0 (el)
MY (1) MY129227A (el)
NO (2) NO323984B1 (el)
NZ (1) NZ507056A (el)
PE (1) PE20001089A1 (el)
PL (1) PL201688B1 (el)
PT (4) PT2266598T (el)
TR (1) TR200003455T2 (el)
TW (1) TW576747B (el)
UA (1) UA72205C2 (el)
WO (1) WO2000010596A1 (el)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770623B1 (en) * 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
AR033639A1 (es) 1998-08-19 2004-01-07 Lilly Co Eli Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis
US20040033950A1 (en) * 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
CA2387693A1 (en) * 1999-09-20 2001-03-29 Eli Lilly And Company Method for monitoring treatment with a parathyroid hormone
US7247609B2 (en) 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
US7015195B2 (en) * 2002-01-10 2006-03-21 Osteotrophin, Llc Treatment of bone disorders with skeletal anabolic drugs
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
CN1852716A (zh) * 2003-09-19 2006-10-25 辉瑞产品公司 包括2-亚烷基-19-去甲基-维生素d衍生物和甲状旁腺激素的组合的药物组合物和方法
US20060189533A1 (en) * 2004-05-10 2006-08-24 Nastech Pharmaceutical Company Inc. Stable pharmaceutical dosage forms of teriparatide
AU2005247369A1 (en) * 2004-05-10 2005-12-08 Mdrna, Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
US20060127320A1 (en) * 2004-05-10 2006-06-15 Nastech Pharmaceutical Company Inc. Method of delivering parathyroid hormone to a human
US20060052305A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. Method of treating osteoporosis using intranasal parathyroid hormone
WO2005112984A2 (en) 2004-05-13 2005-12-01 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents
US7648965B2 (en) 2004-05-14 2010-01-19 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US20060069021A1 (en) * 2004-08-13 2006-03-30 Nastech Pharmaceutical Company Inc. Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs
WO2006073711A2 (en) * 2005-01-06 2006-07-13 Kuros Biosurgery Ag Use of a matrix comprising a contrast agent in soft tissues
US8575101B2 (en) 2005-01-06 2013-11-05 Kuros Biosurgery Ag Supplemented matrices for the repair of bone fractures
CN101217972B (zh) * 2005-05-11 2013-05-29 尤尼基因实验室公司 促进骨形成和保持的方法
US20070173447A1 (en) * 2005-10-25 2007-07-26 Nastech Pharmaceutical Company Inc. Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
EP1945245A2 (en) * 2005-11-10 2008-07-23 The Board of Control of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US20080051332A1 (en) * 2005-11-18 2008-02-28 Nastech Pharmaceutical Company Inc. Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone
US20080119408A1 (en) * 2006-07-07 2008-05-22 Nastech Pharmaceutical Company Inc. Pth formulations for intranasal delivery
EP1961765A1 (en) * 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
MX2009011005A (es) 2007-04-13 2009-11-02 Kuros Biosurgery Ag Sellador polimerico para tejido.
US20110137243A1 (en) * 2007-09-06 2011-06-09 Abbott Cardiovascular Systems Inc. Coating On A Balloon Device
EP2217260B1 (en) * 2007-12-04 2016-11-09 Ben-Gurion University Of The Negev Research And Development Authority Amphiphilic peptide matrices for treatment of osteoporosis
JP2012512812A (ja) 2007-12-28 2012-06-07 クロス・バイオサージェリー・アクチェンゲゼルシャフト フィブリンフォームに組込まれたpdgf融合タンパク質
EP2682125B1 (en) 2009-09-09 2020-11-04 Asahi Kasei Pharma Corporation Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 200 units
AU2009356227A1 (en) 2009-12-07 2012-06-21 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US9295663B2 (en) 2010-07-14 2016-03-29 Abbott Cardiovascular Systems Inc. Drug coated balloon with in-situ formed drug containing microspheres
WO2012111852A1 (ja) * 2011-02-17 2012-08-23 帝人ファーマ株式会社 椎体骨折治療剤及びその評価方法
ES2882852T3 (es) 2011-03-16 2021-12-02 Kuros Biosurgery Ag Formulación farmacéutica para la utilización en la fusión espinal
CN104645318B (zh) 2011-06-07 2021-11-02 旭化成制药株式会社 高纯度含pth冷冻干燥制剂及其制造方法
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
EP3411066A1 (en) * 2016-02-01 2018-12-12 Eli Lilly and Company Parathyroid hormone anti-rankl antibody fusion compounds
CN110520148A (zh) * 2017-02-01 2019-11-29 约翰霍普金斯大学 甲状旁腺激素与退行性椎间盘疾病的再生
EP3685849A4 (en) * 2017-09-22 2021-12-22 Asahi Kasei Pharma Corporation LIQUID PHARMACEUTICAL COMPOSITION CONTAINING TRIPARATIDE WITH EXCELLENT STABILITY
CA3101326C (en) 2018-10-29 2023-08-01 Asahi Kasei Pharma Corporation Method for preventing or treating osteoporosis, characterized by administering teriparatide or salt thereof at a frequency of twice a week
EP4010360A1 (en) 2019-08-09 2022-06-15 Flagship Pioneering Innovations VI, LLC Modulators of parathyroid hormone receptor (pthr1)
GB2590692A (en) * 2019-12-24 2021-07-07 Corthotec Ltd Composition for improved bone fracture healing

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
IL78342A (en) 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
DE3935738A1 (de) 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
US5208041A (en) 1991-05-23 1993-05-04 Allelix Biopharmaceuticals Inc. Essentially pure human parathyroid hormone
US5556940A (en) 1994-06-20 1996-09-17 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
JPH0873376A (ja) * 1994-09-07 1996-03-19 Asahi Chem Ind Co Ltd 骨粗鬆症治療薬
US5747456A (en) * 1994-12-19 1998-05-05 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist
EP0800405A4 (en) * 1994-12-19 1998-11-11 Beth Israel Hospital CONTINUOUS ADMINISTRATION OF LOW DOSES OF HORMONE PARATHYRO DIENNE OR ITS AGONIST
DK0806945T3 (da) * 1994-12-22 2003-08-04 Astrazeneca Ab Terapeutisk præparat til inhalering, indeholdende parathyroideahormon, PTH
JPH08310965A (ja) * 1995-05-16 1996-11-26 Chugai Pharmaceut Co Ltd 骨癒合促進剤
BR9812068A (pt) * 1997-09-09 2000-09-26 Hoffmann La Roche Processo para a cicatrização óssea e restauração de fraturas e utilização de um análogo de polipeptìdeo de peptìdeo (pthrp) relacionado com hormÈnios de paratireóide e seus sais
MY120063A (en) 1997-12-09 2005-08-30 Lilly Co Eli Stabilized teriparatide solutions
US20040033950A1 (en) * 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
AR033639A1 (es) * 1998-08-19 2004-01-07 Lilly Co Eli Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis
US6907597B1 (en) 2000-10-13 2005-06-14 Ati International Srl Method and apparatus for constructing an executable program in memory
US6967759B2 (en) 2001-12-31 2005-11-22 Texas Instruments Incorporated Pulse width modulation sequence generation
JP5796714B2 (ja) 2012-01-13 2015-10-21 株式会社リコー 定着装置及び画像形成装置
EP2949301B1 (en) 2014-05-27 2018-04-18 The Procter and Gamble Company Absorbent core with curved and straight absorbent material areas

Also Published As

Publication number Publication date
DE69904918T2 (de) 2003-11-13
AR033639A1 (es) 2004-01-07
CA2325371A1 (en) 2000-03-02
NO20005947D0 (no) 2000-11-24
HUP0101594A3 (en) 2002-01-28
DK2907522T3 (en) 2017-10-23
US6977077B1 (en) 2005-12-20
PE20001089A1 (es) 2000-11-04
CZ20004134A3 (cs) 2001-08-15
HU230697B1 (hu) 2017-09-28
ATE231000T1 (de) 2003-02-15
CN1205997C (zh) 2005-06-15
PL343595A1 (en) 2001-08-27
CN1308545A (zh) 2001-08-15
KR20010072763A (ko) 2001-07-31
EA003362B1 (ru) 2003-04-24
JP2014139220A (ja) 2014-07-31
IL138829A0 (en) 2001-10-31
HK1030545A1 (en) 2001-05-11
NZ507056A (en) 2003-10-31
DZ2873A1 (fr) 2003-12-15
DE15152726T1 (de) 2015-12-10
JP2015028065A (ja) 2015-02-12
CO5130020A1 (es) 2002-02-27
EP2907522B1 (en) 2017-08-02
US20050197294A1 (en) 2005-09-08
US7163684B2 (en) 2007-01-16
JP2017190332A (ja) 2017-10-19
NO323984B1 (no) 2007-07-30
ID29039A (id) 2001-07-26
PT1769804E (pt) 2012-11-13
DK2907522T1 (da) 2015-10-19
HK1212602A1 (zh) 2016-06-17
PT1059933E (pt) 2003-06-30
EP2266598A1 (en) 2010-12-29
WO2000010596A1 (en) 2000-03-02
JP6177718B2 (ja) 2017-08-09
HRP20000755A2 (en) 2001-02-28
CZ301017B6 (cs) 2009-10-14
AU5575099A (en) 2000-03-14
NO20005947L (no) 2000-11-24
CA2325371C (en) 2004-08-17
NO20072983L (no) 2000-11-24
DK2266598T3 (en) 2017-05-15
TW576747B (en) 2004-02-21
UA72205C2 (uk) 2005-02-15
CY1113343T1 (el) 2016-06-22
PT2266598T (pt) 2017-05-02
HK1102496A1 (en) 2007-11-23
KR100454207B1 (ko) 2004-10-26
PL201688B1 (pl) 2009-04-30
ES2549551T3 (es) 2017-11-27
EP2907522A1 (en) 2015-08-19
AU746277B2 (en) 2002-04-18
DE69904918D1 (de) 2003-02-20
ES2549551T1 (es) 2015-10-29
HU1200430D0 (hu) 2001-11-28
PT2907522T (pt) 2017-10-23
TR200003455T2 (tr) 2001-06-21
JP2011021035A (ja) 2011-02-03
HUP0101594A2 (hu) 2001-11-28
BR9909445A (pt) 2000-12-12
ES2190244T3 (es) 2003-07-16
EP1059933A1 (en) 2000-12-20
EP1059933B1 (en) 2003-01-15
MY129227A (en) 2007-03-30
EA200001015A1 (ru) 2001-02-26
DK1769804T3 (da) 2012-10-15
IL138829A (en) 2011-01-31
ES2393200T3 (es) 2012-12-19
ES2621653T3 (es) 2017-07-04
EP2266598B1 (en) 2017-02-22
DK1059933T3 (da) 2003-04-07
JP2002523375A (ja) 2002-07-30

Similar Documents

Publication Publication Date Title
CY1119552T1 (el) Μεθοδος αυξησης της οστικης σκληροτητας και ακαμψιας και μειωσης των καταγματων
Than et al. Clinical and radiographic parameters associated with best versus worst clinical outcomes in minimally invasive spinal deformity surgery
DE60228737D1 (de) Bilaterale laminoplastie-implantate
EP1205154A3 (en) Osteosynthesis plating apparatus and method with extension plate
DE69609197T2 (de) Zwischenwirbelkörper
IS7770A (is) Hlutleysandi mótefni gegn GDF-8 og notkun theirra
ATE148328T1 (de) Knochenchirurgische haltevorrichtung
EE04221B1 (et) Östrogeeni kasutamine ravimi valmistamiseks füüsiliste seisundite raviks menopausijärgsetel isikutel
AU6208499A (en) Anterior osteosynthesis plate for lumbar vertebrae or sacral lumbar vertebra andinstrument for positioning same
FR2827500B1 (fr) Plaque d'osteosynthese de l'extremite superieure de l'humerus
DK1663037T3 (da) Ortopædisk implantat og knogleskruesamling
PL1615598T3 (pl) Urządzenie dla spondylodezy
BR9711829A (pt) Implante cirúrgico contendo um marcador radiopaco ressorvìvel.
ATE309753T1 (de) Wirbelsäulen-osteosynthesesystem insbesondere zur vorderen fixierung
ATE460910T1 (de) Gelenksprothese für den hintenliegenden wirbelsäulenbereich
DE50302686D1 (en) System für die osteosynthese
WO2004024009A8 (en) Bone plates
DE60018988D1 (de) Wirbelkäfig zur immobilisierung der wirbelsäule
ATE440572T1 (de) Endstück für knochen-fusionsimplantat
CY1118882T1 (el) Μεθοδος αυξησης της οστικης σκληροτητας και ακαμψιας και μειωσης των καταγματων
AU2003251729A8 (en) Use of antibodies against flt-1 for the treatment of osteoporosis
EP1295605A3 (en) Method of increasing bone toughness and stiffness and reducing fractures
MD1270F1 (en) Method for treatment of the hand navicular bone pseudarthrosis
ES1035047Y (es) Fijador espinal para la correcion de desestabilizaciones de vertebras.
DE9320741U1 (de) Vorrichtung zur Osteosynthese von Knochenfragmenten, insbesondere zur Fixation von Knochenfrakturen